Novo Holdings A/S

Novo Holdings A/S discloses dealings in 15 companies, chiefly Cyteir Therapeutics, Inc., IO Biotech, Inc. and Spruce Biosciences, Inc. The record holds 32 filings, for trades running from 19 May 2021 to 1 May 2026.

The open-market side counts 5 purchases for €21.0M alongside 20 sales for €98.1M. The totals exclude 3 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings 1 purchase and no sales.

The median purchase comes to €5.8M. Of 4 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 5 May 2026 with an open-market purchase (€8.5M) in Avalyn Pharma Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.